Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Anavo Therapeutics

Request full access

Phosphatase-targeted allosteric modulators for oncology therapeutics.

Leiden, NetherlandsFounded 2020Biotech & Life Sciences

About Anavo Therapeutics

Anavo Therapeutics is a biopharmaceutical company focused on systematically drugging phosphatases, a class of enzymes long considered undruggable. The company was founded in 2020 with operations starting in 2021, and is led by co-founders Dr. Birgit Zech (CEO) and Dr. Gerhard Müller (CSO), who previously collaborated as co-founders of Gotham Therapeutics. The founding team also includes Claus Schalper, a finance expert and serial biotech entrepreneur. Headquartered in Leiden, Netherlands, Anavo also operates an R&D hub in Heidelberg, Germany, to leverage proximity to major European research centers.

The company's core asset is its proprietary IGNITE platform, which is engineered to discover and develop allosteric modulators that target phosphatases. Unlike kinase inhibitors, which have become a multi-billion dollar market, phosphatases have been a challenging target class. Anavo's approach bypasses the enzymes' active sites, combining deep knowledge of phosphatase biology with high-throughput screening and advanced protein structural methods to create first-in-class small molecule drugs. The primary therapeutic focus for its in-house pipeline is oncology, with plans to expand into other indications through strategic partnerships.

Anavo Therapeutics launched in April 2021 with a significant seed financing round of €20 million (approximately $24 million), co-led by M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures. The company extended this seed round in May 2023, raising an additional €8.5 million and bringing the total to €28 million (approximately $33.3 million). This extension introduced MRL Ventures Fund, the venture arm of Merck & Co., Inc., as a new investor. These funds are designated to advance the company's proprietary oncology programs towards clinical development and to further build out its IGNITE platform.

Source: Dealroom company data

At a glance

Status
Operational
Employees
26
Open positions
1
Dealroom signal
49.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC May 2023 $9.3M $120M Inkef · M Ventures · Bioqube Ventures · Taiho Pharma ↗
SEED✓Equity / VC Apr 2021 $24M $96M Inkef · Bioqube Ventures · M Ventures · Taiho Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearProfitMargin
2026 —
2025 —
2024 —
2023 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Anavo Therapeutics website traffic

Latest recorded traffic for Anavo Therapeutics is 1.7K monthly website visits, up 107.3% over the last three months. Anavo Therapeutics's team grew 0% over the past year.

Latest monthly visits1.7K 3-month web change+107.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Anavo Therapeutics in the Leiden ecosystem

Live from Dealroom

The Anavo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed6 investors entered at this stage

  • Inkef
  • Bioqube Ventures
  • M Ventures
  • Taiho Ventures
  • Taiho Pharma
  • MRL Ventures
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇩🇪 Germany47.6%
🇺🇸 United States23.8%
🇳🇱 Netherlands9.5%
🇬🇧 United Kingdom4.8%
🇨🇭 Switzerland4.8%
Top 5 of 6 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Anavo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Anavo Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.